Treatment of Central Precocious Puberty Using Gonadotropin-releasing Hormone Agonists

Journal for Nurse Practitioners

Volumn 11, Issue 7, 2015, Pages 686-694

  Cafasso, Mandi ^a   Elder, Deborah A ^b   Blum, Samantha ^b   Weis, Tammy ^b   Hornung, Lindsey ^a   Khoury, Jane C ^c   Stenger, Peggy J ^b   Rose, Susan R ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Division of Endocrinology   (United States)

^c RTI International   (United States)

Author keywords

GnRHa therapy; Pediatrics; Precocious puberty short stature

Indexed keywords

EID: 84937523558     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2015.05.001     Document Type: Article

References (26)

1. Carel J.C., Eugster E.A., Rogol A., Ghizzoni L., Palmert M.R. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009, 123(4):E752-E762.
2. Lee P.A., Neely E.K., Fuqua J., et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011, 2011(1):7.
3. Lee P.A., Houk C.P. Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty. Treat Endocrinol 2006, 5(5):287-296.
4. Lazar L., Padoa A., Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. JClin Endocrinol Metab 2007, 92(9):3483-3489.
5. Carel J.C., Lahlou N., Roger M., Chaussain J.L. Precocious puberty and statural growth. Hum Reprod Update 2004, 10(2):135-147.
6. Chalumeau M., Chemaitilly W., Trivin C., Adan L., Breart G., Brauner R. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics 2002, 109(1):61-67.
7. Sperling M. Disorders of growth hormone/insulin-like growth factor secretion and action. Pediatric Endocrinology. 3rd ed 2008, 305. Saunders/Elsevier, Philadelphia. M. Sperling (Ed.).
8. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. JBiomed Informat 2009, 42(2):377-381.
9. Sathasivam A., Garibaldi L., Shapiro S., Godbold J., Rapaport R. Leuprolide stimulation testing for the evaluation of early female sexual maturation. Clin Endocrinol (Oxf) 2010, 73(3):375-381.
10. US Centers for Disease Control and Prevention. Growth chart SAS program. Accessed March 12, 2013. http://www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm/.
11. Hornung R.W., Reed L.D. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hygiene 1990, 5(1):46-51.
12. Kuczmarski R.J., Ogden C.L., Guo S.S., et al. CDC Growth charts for the United States: methods and development. Vital Health Statistics 11 2002, (246):1-190.
13. Ankarberg-Lindgren C., Norjavaara E. Changes of diurnal rhythm and levels of total and free testosterone secretion from pre to late puberty in boys: testis size of 3 ml is a transition stage to puberty. Eur J Endocrinol 2004, 151(6):747-757.
14. Lee P.A., Klein K., Mauras N., et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. JClin Endocrinol Metab 2012, 97(5):1572-1580.
15. Neely E.K., Hintz R.L., Parker B., et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. JPediatr 1992, 121(4):634-640.
16. Teutonico D., Montanari S., Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv 2012, 9(3):343-354.
17. Carel J.C., Lahlou N., Jaramillo O., et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). JClin Endocrinol Metab 2002, 87(9):4111-4116.
18. Mericq V., Lammoglia J.J., Unanue N., et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol (Oxf) 2009, 71(5):686-690.
19. Carel J.C., Blumberg J., Seymour C., et al. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006, 154(1):119-124.
20. Martinez-Aguayo A., Hernandez M.I., Beas F., et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. JPediatr Endocrinol Metabol 2006, 19(8):963-970.
21. Badaru A., Wilson D.M., Bachrach L.K., et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. JClin Endocrinol Metab 2006, 91(5):1862-1867.
22. Fuld K., Chi C., Neely E.K. Arandomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. JPediatr 2011, 159(6):982-987. e981.
23. Fugua J. Treatment and outcomes of precocious puberty: an update. JClin Endocrinol Metabol 2013, 98(6):2198-2207.
24. Foster C.M. Does lupron dosage make a difference in outcome when treating children with precocious puberty?. JClin Endocrinol Metabol 2006, 91(5):1667-1668.
25. Lewis K.A., Eugster E.A. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. JPediatr 2013, 162(3):562-565.
26. Mul D., de Muinck Keizer-Schrama S.M., Oostdijk W., Drop S.L. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty. Horm Res 1999, 51(6):270-276.